The PCOS diagnostic market size was valued at USD 2.98 billion in 2024 and is expected to reach USD 4.41 billion by 2032, growing at a CAGR of 5.03% over 2025-2032.
The PCOS diagnostic market growth is gaining momentum owing to growing awareness towards women’s requirement for reproductive health, prevalence rate of hormonal disorder incidence, and strengthening network of diagnostic services in developed as well as in developing economies. PCOS affects an estimated 1 in 10 reproductive age females globally, and the demand for hormonal assays, imaging techniques, and metabolic panel testing is contributing to the PCOS diagnostic market growth.
In February 2024, Hologic Inc. launched a gynecologic-focused ultrasound platform based on artificial intelligence (AI) to improve diagnostic precision and assist in early detection of PCOS, confirming a major tech-facilitated care delivery in the PCOS diagnosis market.
The increasing incidence of infertility, delayed pregnancy, and metabolic disorders associated with obesity has also led to an increase in volumes of diagnostic tests. Furthermore, the global PCOS diagnostic market is experiencing an increase in R&D expenditure on novel biomarkers and multiplex hormone panels. For instance, Thermo Fisher Scientific and Roche are actively investing in women’s health diagnostics solutions. Regulatory guidelines such as the NIH criteria and Rotterdam Consensus are supportive, and this helps with provider adoption. Rising government investment, femtech growth, and AI integration in diagnostic interpretation are also enhancing the PCOS diagnostic market share globally.
In April 2024, Myriad Genetics joined in on the race, announcing a new addition to its women’s health diagnostics suite, offering genetic tests for PCOS risk and associated endocrine conditions driven by the innovation landscape of PCOS diagnostic companies.
Drivers:
Rising Diagnostic Awareness and Technological Innovation Are Boosting Market Demand
The PCOS diagnostics market is developing with the growing prevalence of hormonal and metabolic disorders in women of reproductive age and increased public and clinical awareness. Between 60 and 70% of PCOS cases are believed to go undiagnosed worldwide, and governments and health associations have been organizing awareness initiatives and early detection for PCOS since. The need for precise diagnostics has never been greater, and there are new developments in multiplex hormone testing, transvaginal 3D imaging, and genetic risk profiling.
Entities such as Ansh Labs and Roberts Stago are introducing new assays targeting anti-Müllerian hormone (AMH) and insulin resistance, which leads to earlier detection. Further, more and more is being invested in femtech and women’s health diagnostics, like the USD 1.5 billion that has poured into women’s health startups globally in 2023 to drive R&D. To speed up product availability, regulatory bodies like the FDA and EMA have also simplified diagnostic approval pathways. These are the collective factors driving the PCOS diagnostic market growth, which in turn helps in a better PCOS diagnostic market analysis and hence is widening the PCOS diagnostic market size globally.
Restraints:
Limited Access and Lack of Standardized Testing Protocols Impede Market Expansion
Some of the main factors that are likely to restrict the PCOS diagnosis market growth include the disparities in access to diagnostic care and the lack of uniform diagnostic criteria, notwithstanding the technological advancements. In low- and middle-income countries, the lack of availability of specialized hormone tests and imaging hampers diagnosis. Rural healthcare facilities, for instance, usually do not have the technologies to perform transvaginal ultrasounds or endocrine assays, so that they represent a supply-side chokepoint. Additionally, inconsistent application of diagnostic criteria (including differences among NIH, Rotterdam, and AE-PCOS Society criteria) results in inconsistent diagnosis.
A study published in 2022 in The Journal of Clinical Endocrinology & Metabolism found that more than 40% of doctors rely on problematic PCOS criteria, resulting in the phenomenon of both under- and over-diagnosis. Lack of reimbursement and access to complete diagnostic panels is also a barrier in many systems of care. Although R&D investment is increasing, it remains disproportionately biased toward fertility-centric diagnostics, and there is little to no investment in metabolic or psychiatric symptom tracking, key to holistic PCOS care. These are a drag on the utilization of novel diagnostics in underserved market territories that have arrested the PCOS diagnostic market analysis despite increasing demand.
By Type of Diagnostic Test
The hormone tests segment held a share of 35% in the PCOS diagnostics market in 2024, owing to the pivotal role of hormone tests in determining hormonal irregularities, including high levels of LH/FSH ratios, testosterone, and AMH in women. They are the first-line strategy for the diagnosis of PCOS and are broadly used in clinical laboratories and hospitals.
The category seeing the fastest growth in demand is the medical testing category, created by a surge in the interest in personalized medicine to genomic markers that indicate genetic predisposition for early identification. Increasing research in genomics, and integration of PCOS-specific gene panels further drive growth in this domain.
By Drug Class
The oral contraceptives segment accounted for the largest market share of around 38% in 2024, since they are prescribed as the first line of treatment for the relief of symptoms such as irregular menstruation and hyperandrogenism. Their broad availability and incorporation in standard protocols of care support their supremacy.
The highest expanding segment is insulin-sensitizing agents, which is propelled by the increasing disease burden of insulin resistance among the PCOS patients and the emerging trend of metformin being used as a therapeutic option for the treatment of metabolic symptoms.
By Surgery Type
Laparoscopic Ovarian Drilling (LOD) was the most favoured treatment among surgical techniques, capturing 65.9% of the PCOS diagnostic market trends in 2024. Its less invasive nature and high efficiency to induce ovulation in drug-resistant patients, explain its clinical use versus classical approaches.
The fastest growth segment is LOD, due to the increasing incidence of infertility and its growing acceptance among developing countries where the availability of advanced fertility treatments is very limited.
By Distribution Channel
Hospital pharmacies held the leading position in the distribution channel segment in 2024, as there is a surge in the number of patients who are diagnosed and prescribed through hospital-based endocrinology and gynecology departments.
The fastest growing channel is online providers, due to the rise of telemedicine, home testing kits, and e-pharmacy players, making it easier to obtain detection and treatment solutions for PCOS. This trend is being reinforced by the digital health revolution and increased penetration in urban and semi-urban areas.
The PCOS diagnostic market in North America was the largest in 2024, owing to established healthcare infrastructure, high awareness about PCOS, and availability of advanced diagnostic technologies.
The U.S. PCOS diagnostic market size was valued at USD 1.11 billion in 2024 and is expected to reach USD 1.61 billion by 2032, growing at a CAGR of 4.73% over 2025-2032. The U.S. holds the dominant PCOS diagnostic market share due to the high prevalence of the disorder, the high number of diagnosed PCOS patients, awareness programs for PCOS, and reimbursement policies by insurance. An estimated 6 million to 10 million women in the U.S. have PCOS, and demand is being driven by increasing use of hormonal and imaging diagnostics. Canada is part of the solution, too, with publicly funded women’s health programs and broad access to genetic testing. The existence of well-established players, as Hologic, Thermo Fisher, and LabCorp, in the PCOS diagnostic market in the region also contributes to market growth. The US PCOS diagnostic market is boosted by widespread screening and use of algorithm-based diagnostic pathways.
Europe held a significant share of the global PCOS diagnostic market in 2024, owing to overall healthcare systems and a rise in clinical research on women's hormone disorders. Germany and the UK are among the top contributors, as these countries use transvaginal ultrasound and hormone panels extensively in gynecological practice.
Germany, in particular, has a strong diagnostics manufacturing foundation and has already begun adopting AI-based screening tools. The fastest-rising country in Europe is France, with growing government spending on reproductive health services and a population of females more focused on their fertility, pushing the rise in PCOS tests in the country. Europe, too, is experiencing a rising number of public-private partnerships in the field of endocrinology research, which in turn propels the market.
The Asia Pacific is the fastest-growing region in the global PCOS diagnostic market, owing to an increase in awareness, rising urbanization, and expanded healthcare accessibility in the developing economies.
India is a leading market in the region with almost one in five women of reproductive age affected by PCOS and a growing appeal for hormonal and metabolic testing. Adoption is being driven by government health programmes and private fertility clinics. China is another significant market, due to the proliferation of diagnostic laboratories and increasing fertility treatments. In Japan, sex, gender, and the genome are also the “Next Generation in Japan” with a focus on personalized medicine and genomic testing for reproductive disorders. The burgeoning development in the region is unthinkable phenomenal due to better health care facilities and the increasing burden of obesity and insulin resistance in women.
Leading PCOS diagnostics companies in the market include F. Hoffmann-La Roche Ltd, Quest Diagnostics, Thermo Fisher Scientific Inc., Siemens Healthineers, Bio-Rad Laboratories, Hologic Inc., Vitrolife, Myriad Genetics Inc., Ansh Labs, Diagnostica Stago Inc., Beckman Coulter Inc., Randox Laboratories Ltd., GE Healthcare, Laboratory Corporation of America Holdings, SRL Diagnostics, Perrigo Company plc, Lupin, Astellas Pharma Inc., Organon, and ADVANZ PHARMA.
In June 2024, Beckman Coulter announced the launch of a new high-sensitivity Anti-Müllerian Hormone (AMH) assay, aimed at improving ovarian reserve assessment and early PCOS diagnosis in women of reproductive age.
In May 2024, Vitrolife AB collaborated with a fertility clinic chain in Europe to integrate AI-based hormonal profiling into routine PCOS diagnostic workflows, enhancing diagnostic accuracy and cycle monitoring.
| Report Attributes | Details |
|---|---|
| Market Size in 2024 | USD 2.98 billion |
| Market Size by 2032 | USD 4.41 billion |
| CAGR | CAGR of 5.03% From 2025 to 2032 |
| Base Year | 2024 |
| Forecast Period | 2025-2032 |
| Historical Data | 2021-2023 |
| Report Scope & Coverage | Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook |
| Key Segments | • By Type of Diagnostic Test (Hormone Tests (Luteinizing Hormone (LH), Follicle-Stimulating Hormone (FSH), Testosterone, Anti-Müllerian Hormone (AMH), and Estrogen), Blood Tests (Fasting Insulin, Glucose Tolerance Test, Lipid Profile, and HbA1c), Imaging Tests (Transvaginal Ultrasound, Pelvic Ultrasound), Pelvic Examination, Genetic Testing, and Other Tests (Thyroid Function Tests (TSH, T3, T4), Prolactin Test, DHEAS (Dehydroepiandrosterone Sulfate))) • By Drug Class (Oral Contraceptives, Antiandrogens, Insulin-Sensitizing Agents, Antidepressants, and Anti-Obesity Medications) • By Surgery Type (Ovarian Wedge Resection, Laparoscopic Ovarian Drilling (LOD)) • By Distribution Channel (Hospital Pharmacies, Drug Stores & Retail Pharmacies, and Online Providers) |
| Regional Analysis/Coverage | North America (U.S., Canada), Europe (Germany, France, UK, Italy, Spain, Russia, Poland, Rest of Europe), Asia Pacific (China, India, Japan, South Korea, Australia, ASEAN Countries, Rest of Asia Pacific), Middle East & Africa (UAE, Saudi Arabia, Qatar, Egypt, South Africa, Rest of Middle East & Africa), Latin America (Brazil, Argentina, Mexico, Colombia, Rest of Latin America) |
| Company Profiles | F. Hoffmann-La Roche Ltd, Quest Diagnostics, Thermo Fisher Scientific Inc., Siemens Healthineers, Bio-Rad Laboratories, Hologic Inc., Vitrolife, Myriad Genetics Inc., Ansh Labs, Diagnostica Stago Inc., Beckman Coulter Inc., Randox Laboratories Ltd., GE Healthcare, Laboratory Corporation of America Holdings, SRL Diagnostics, Perrigo Company plc, Lupin, Astellas Pharma Inc., Organon, and ADVANZ PHARMA. |
Ans: The PCOS diagnostic market size is expanding steadily due to increased screening and hormonal testing volumes across global healthcare systems. The rising prevalence of PCOS in reproductive-age women continues to drive demand for diagnostics.
Ans: Hormone assays (like LH, FSH, AMH) and pelvic ultrasounds are the most frequently used diagnostic methods for PCOS due to their clinical accuracy and wide availability.
Ans: Increasing cases of insulin resistance, delayed pregnancies, and growing awareness of endocrine disorder diagnostics are major drivers for the PCOS diagnostic market growth.
Ans: Global demand is shifting toward non-invasive, at-home diagnostics and AI-enabled hormonal analysis, making PCOS screening more accessible and patient-centric.
Ans: Key PCOS diagnostic companies include F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific, Labcorp, Ansh Labs, and Hologic Inc., with a focus on hormone and imaging technologies.
Table Of Contents
1. Introduction
1.1 Market Definition & Scope
1.2 Research Assumptions & Abbreviations
1.3 Research Methodology
2. Executive Summary
2.1 Market Snapshot
2.2 Market Absolute $ Opportunity Assessment & Y-o-Y Analysis, 2021–2032
2.3 Market Size & Forecast, By Segmentation, 2021–2032
2.3.1 Market Size By Type of Diagnostic Test
2.3.2 Market Size By Drug Class
2.3.3 Market Size By Surgery Type
2.3.4 Market Size By Distribution Channel
2.4 Market Share & BPS Analysis By Region, 2024
2.5 Industry Growth Scenarios – Conservative, Likely & Optimistic
2.6 Industry CxO’s Perspective
3. Market Overview
3.1 Market Dynamics
3.1.1 Drivers
3.1.2 Restraints
3.1.3 Opportunities
3.1.4 Key Market Trends
3.2 Industry PESTLE Analysis
3.3 Key Industry Forces (Porter’s) Impacting Market Growth
3.4 Industry Supply Chain Analysis
3.4.1 Raw Material Suppliers
3.4.2 Manufacturers
3.4.3 Distributors/Suppliers
3.4.4 Customers/End-Users
3.5 Industry Life Cycle Assessment
3.6 Parent Market Overview
3.7 Market Risk Assessment
4. Statistical Insights & Trends Reporting
4.1 Insurance Coverage & Diagnostic Affordability
4.1.1 Regional Coverage Landscape for PCOS Diagnostics
4.1.2 Diagnostic Cost Trends and Out-of-Pocket Spending
4.2 Diagnostic Awareness and Early Detection Trends
4.2.1 Age Group and Demographic Testing Patterns
4.2.2 PCOS Screening Campaigns and Education Initiatives
4.3 Innovation and Adoption of Diagnostic Technologies
4.3.1 Expansion of At-Home and Femtech Diagnostic Kits
4.3.2 Advances in Imaging and Hormone Profiling
5. PCOS Diagnostic Market Segmental Analysis & Forecast, By Type of Diagnostic Test, 2021 – 2032, Value (USD Billion)
5.1 Introduction
5.2 Hormone Tests
5.2.1 Key Trends
5.2.2 Market Size & Forecast, 2021 – 2032
5.2.1 Luteinizing Hormone (LH)
5.2.1.1 Key Trends
5.2.1.2 Market Size & Forecast, 2021 – 2032
5.2.2 Follicle-Stimulating Hormone (FSH)
5.2.2.1 Key Trends
5.2.2.2 Market Size & Forecast, 2021 – 2032
5.2.3 Testosterone
5.2.3.1 Key Trends
5.2.3.2 Market Size & Forecast, 2021 – 2032
5.2.4 Anti-Müllerian Hormone (AMH)
5.2.4.1 Key Trends
5.2.4.2 Market Size & Forecast, 2021 – 2032
5.2.5 Estrogen
5.2.5.1 Key Trends
5.2.5.2 Market Size & Forecast, 2021 – 2032
5.3 Blood Tests
5.3.1 Key Trends
5.3.2 Market Size & Forecast, 2021 – 2032
5.3.3 Fasting Insulin
5.3.3.1 Key Trends
5.3.3.2 Market Size & Forecast, 2021 – 2032
5.3.4 Glucose Tolerance Test
5.3.4.1 Key Trends
5.3.4.2 Market Size & Forecast, 2021 – 2032
5.3.5 Lipid Profile
5.3.5.1 Key Trends
5.3.5.2 Market Size & Forecast, 2021 – 2032
5.3.6 HbA1c
5.3.6.1 Key Trends
5.3.6.2 Market Size & Forecast, 2021 – 2032
5.4 Imaging Tests
5.4.1 Key Trends
5.4.2 Market Size & Forecast, 2021 – 2032
5.4.3 Transvaginal Ultrasound
5.4.3.1 Key Trends
5.4.3.2 Market Size & Forecast, 2021 – 2032
5.4.4 Pelvic Ultrasound
5.4.4.1 Key Trends
5.4.4.2 Market Size & Forecast, 2021 – 2032
5.5 Pelvic Examination
5.5.1 Key Trends
5.5.2 Market Size & Forecast, 2021 – 2032
5.6 Genetic Testing
5.6.1 Key Trends
5.6.2 Market Size & Forecast, 2021 – 2032
5.7 Other Tests (Thyroid Function Tests (TSH, T3, T4), Prolactin Test, DHEAS (Dehydroepiandrosterone Sulfate))
5.7.1 Key Trends
5.7.2 Market Size & Forecast, 2021 – 2032
6. PCOS Diagnostic Market Segmental Analysis & Forecast, By Drug Class, 2021 – 2032, Value (USD Billion)
6.1 Introduction
6.2 Oral Contraceptives
6.2.1 Key Trends
6.2.2 Market Size & Forecast, 2021 – 2032
6.3 Antiandrogens
6.3.1 Key Trends
6.3.2 Market Size & Forecast, 2021 – 2032
6.4 Insulin-Sensitizing Agents
6.4.1 Key Trends
6.4.2 Market Size & Forecast, 2021 – 2032
6.5 Antidepressants
6.5.1 Key Trends
6.5.2 Market Size & Forecast, 2021 – 2032
6.6 Anti-Obesity Medications
6.6.1 Key Trends
6.6.2 Market Size & Forecast, 2021 – 2032
7. PCOS Diagnostic Market Segmental Analysis & Forecast, By Surgery Type, 2021 – 2032, Value (USD Billion)
7.1 Introduction
7.2 Ovarian Wedge Resection
7.2.1 Key Trends
7.2.2 Market Size & Forecast, 2021 – 2032
7.3 Laparoscopic Ovarian Drilling (LOD)
7.3.1 Key Trends
7.3.2 Market Size & Forecast, 2021 – 2032
8. PCOS Diagnostic Market Segmental Analysis & Forecast, By Distribution Channel, 2021 – 2032, Value (USD Billion)
8.1 Introduction
8.2 Hospital Pharmacies
8.2.1 Key Trends
8.2.2 Market Size & Forecast, 2021 – 2032
8.3 Drug Stores & Retail Pharmacies
8.3.1 Key Trends
8.3.2 Market Size & Forecast, 2021 – 2032
8.4 Online Providers
8.4.1 Key Trends
8.4.2 Market Size & Forecast, 2021 – 2032
9. PCOS Diagnostic Market Segmental Analysis & Forecast By Region, 2021 – 2025, Value (USD Billion)
9.1 Introduction
9.2 North America
9.2.1 Key Trends
9.2.2 PCOS Diagnostic Market Size & Forecast, By Type of Diagnostic Test, 2021 – 2032
9.2.3 PCOS Diagnostic Market Size & Forecast, By Drug Class, 2021 – 2032
9.2.4 PCOS Diagnostic Market Size & Forecast, By Surgery Type, 2021 – 2032
9.2.5 PCOS Diagnostic Market Size & Forecast, By Distribution Channel, 2021 – 2032
9.2.6 PCOS Diagnostic Market Size & Forecast, By Country, 2021 – 2032
9.2.6.1 USA
9.2.6.1.1 PCOS Diagnostic Market Size & Forecast, By Type of Diagnostic Test, 2021 – 2032
9.2.6.1.2 PCOS Diagnostic Market Size & Forecast, By Drug Class, 2021 – 2032
9.2.6.1.3 PCOS Diagnostic Market Size & Forecast, By Surgery Type, 2021 – 2032
9.2.6.1.4 PCOS Diagnostic Market Size & Forecast, By Distribution Channel, 2021 – 2032
9.2.6.2 Canada
9.2.6.2.1 PCOS Diagnostic Market Size & Forecast, By Type of Diagnostic Test, 2021 – 2032
9.2.6.2.2 PCOS Diagnostic Market Size & Forecast, By Drug Class, 2021 – 2032
9.2.6.2.3 PCOS Diagnostic Market Size & Forecast, By Surgery Type, 2021 – 2032
9.2.6.2.4 PCOS Diagnostic Market Size & Forecast, By Distribution Channel, 2021 – 2032
9.3 Europe
9.3.1 Key Trends
9.3.2 PCOS Diagnostic Market Size & Forecast, By Type of Diagnostic Test, 2021 – 2032
9.3.3 PCOS Diagnostic Market Size & Forecast, By Drug Class, 2021 – 2032
9.3.4 PCOS Diagnostic Market Size & Forecast, By Surgery Type, 2021 – 2032
9.3.5 PCOS Diagnostic Market Size & Forecast, By Distribution Channel, 2021 – 2032
9.3.6 PCOS Diagnostic Market Size & Forecast, By Country, 2021 – 2032
9.3.6.1 Germany
9.3.6.1.1 PCOS Diagnostic Market Size & Forecast, By Type of Diagnostic Test, 2021 – 2032
9.3.6.1.2 PCOS Diagnostic Market Size & Forecast, By Drug Class, 2021 – 2032
9.3.6.1.3 PCOS Diagnostic Market Size & Forecast, By Surgery Type, 2021 – 2032
9.3.6.1.4 PCOS Diagnostic Market Size & Forecast, By Distribution Channel, 2021 – 2032
9.3.6.2 UK
9.3.6.2.1 PCOS Diagnostic Market Size & Forecast, By Type of Diagnostic Test, 2021 – 2032
9.3.6.2.2 PCOS Diagnostic Market Size & Forecast, By Drug Class, 2021 – 2032
9.3.6.2.3 PCOS Diagnostic Market Size & Forecast, By Surgery Type, 2021 – 2032
9.3.6.2.4 PCOS Diagnostic Market Size & Forecast, By Distribution Channel, 2021 – 2032
9.3.6.3 France
9.3.6.3.1 PCOS Diagnostic Market Size & Forecast, By Type of Diagnostic Test, 2021 – 2032
9.3.6.3.2 PCOS Diagnostic Market Size & Forecast, By Drug Class, 2021 – 2032
9.3.6.3.3 PCOS Diagnostic Market Size & Forecast, By Surgery Type, 2021 – 2032
9.3.6.3.4 PCOS Diagnostic Market Size & Forecast, By Distribution Channel, 2021 – 2032
9.3.6.4 Italy
9.3.6.4.1 PCOS Diagnostic Market Size & Forecast, By Type of Diagnostic Test, 2021 – 2032
9.3.6.4.2 PCOS Diagnostic Market Size & Forecast, By Drug Class, 2021 – 2032
9.3.6.4.3 PCOS Diagnostic Market Size & Forecast, By Surgery Type, 2021 – 2032
9.3.6.4.4 PCOS Diagnostic Market Size & Forecast, By Distribution Channel, 2021 – 2032
9.3.6.5 Spain
9.3.6.5.1 PCOS Diagnostic Market Size & Forecast, By Type of Diagnostic Test, 2021 – 2032
9.3.6.5.2 PCOS Diagnostic Market Size & Forecast, By Drug Class, 2021 – 2032
9.3.6.5.3 PCOS Diagnostic Market Size & Forecast, By Surgery Type, 2021 – 2032
9.3.6.5.4 PCOS Diagnostic Market Size & Forecast, By Distribution Channel, 2021 – 2032
9.3.6.6 Russia
9.3.6.6.1 PCOS Diagnostic Market Size & Forecast, By Type of Diagnostic Test, 2021 – 2032
9.3.6.6.2 PCOS Diagnostic Market Size & Forecast, By Drug Class, 2021 – 2032
9.3.6.6.3 PCOS Diagnostic Market Size & Forecast, By Surgery Type, 2021 – 2032
9.3.6.6.4 PCOS Diagnostic Market Size & Forecast, By Distribution Channel, 2021 – 2032
9.3.6.7 Poland
9.3.6.7.1 PCOS Diagnostic Market Size & Forecast, By Type of Diagnostic Test, 2021 – 2032
9.3.6.7.2 PCOS Diagnostic Market Size & Forecast, By Drug Class, 2021 – 2032
9.3.6.7.3 PCOS Diagnostic Market Size & Forecast, By Surgery Type, 2021 – 2032
9.3.6.7.4 PCOS Diagnostic Market Size & Forecast, By Distribution Channel, 2021 – 2032
9.3.6.8 Rest of Europe
9.3.6.8.1 PCOS Diagnostic Market Size & Forecast, By Type of Diagnostic Test, 2021 – 2032
9.3.6.8.2 PCOS Diagnostic Market Size & Forecast, By Drug Class, 2021 – 2032
9.3.6.8.3 PCOS Diagnostic Market Size & Forecast, By Surgery Type, 2021 – 2032
9.3.6.8.4 PCOS Diagnostic Market Size & Forecast, By Distribution Channel, 2021 – 2032
9.4 Asia-Pacific
9.4.1 Key Trends
9.4.2 PCOS Diagnostic Market Size & Forecast, By Type of Diagnostic Test, 2021 – 2032
9.4.3 PCOS Diagnostic Market Size & Forecast, By Drug Class, 2021 – 2032
9.4.4 PCOS Diagnostic Market Size & Forecast, By Surgery Type, 2021 – 2032
9.4.5 PCOS Diagnostic Market Size & Forecast, By Distribution Channel, 2021 – 2032
9.4.6 PCOS Diagnostic Market Size & Forecast, By Country, 2021 – 2032
9.4.6.1 China
9.4.6.1.1 PCOS Diagnostic Market Size & Forecast, By Type of Diagnostic Test, 2021 – 2032
9.4.6.1.2 PCOS Diagnostic Market Size & Forecast, By Drug Class, 2021 – 2032
9.4.6.1.3 PCOS Diagnostic Market Size & Forecast, By Surgery Type, 2021 – 2032
9.4.6.1.4 PCOS Diagnostic Market Size & Forecast, By Distribution Channel, 2021 – 2032
9.4.6.2 India
9.4.6.2.1 PCOS Diagnostic Market Size & Forecast, By Type of Diagnostic Test, 2021 – 2032
9.4.6.2.2 PCOS Diagnostic Market Size & Forecast, By Drug Class, 2021 – 2032
9.4.6.2.3 PCOS Diagnostic Market Size & Forecast, By Surgery Type, 2021 – 2032
9.4.6.2.4 PCOS Diagnostic Market Size & Forecast, By Distribution Channel, 2021 – 2032
9.4.6.3 Japan
9.4.6.3.1 PCOS Diagnostic Market Size & Forecast, By Type of Diagnostic Test, 2021 – 2032
9.4.6.3.2 PCOS Diagnostic Market Size & Forecast, By Drug Class, 2021 – 2032
9.4.6.3.3 PCOS Diagnostic Market Size & Forecast, By Surgery Type, 2021 – 2032
9.4.6.3.4 PCOS Diagnostic Market Size & Forecast, By Distribution Channel, 2021 – 2032
9.4.6.4 South Korea
9.4.6.4.1 PCOS Diagnostic Market Size & Forecast, By Type of Diagnostic Test, 2021 – 2032
9.4.6.4.2 PCOS Diagnostic Market Size & Forecast, By Drug Class, 2021 – 2032
9.4.6.4.3 PCOS Diagnostic Market Size & Forecast, By Surgery Type, 2021 – 2032
9.4.6.4.4 PCOS Diagnostic Market Size & Forecast, By Distribution Channel, 2021 – 2032
9.4.6.5 Australia
9.4.6.5.1 PCOS Diagnostic Market Size & Forecast, By Type of Diagnostic Test, 2021 – 2032
9.4.6.5.2 PCOS Diagnostic Market Size & Forecast, By Drug Class, 2021 – 2032
9.4.6.5.3 PCOS Diagnostic Market Size & Forecast, By Surgery Type, 2021 – 2032
9.4.6.5.4 PCOS Diagnostic Market Size & Forecast, By Distribution Channel, 2021 – 2032
9.4.6.6 ASEAN Countries
9.4.6.6.1 PCOS Diagnostic Market Size & Forecast, By Type of Diagnostic Test, 2021 – 2032
9.4.6.6.2 PCOS Diagnostic Market Size & Forecast, By Drug Class, 2021 – 2032
9.4.6.6.3 PCOS Diagnostic Market Size & Forecast, By Surgery Type, 2021 – 2032
9.4.6.6.4 PCOS Diagnostic Market Size & Forecast, By Distribution Channel, 2021 – 2032
9.4.6.7 Rest of Asia-Pacific
9.4.6.7.1 PCOS Diagnostic Market Size & Forecast, By Type of Diagnostic Test, 2021 – 2032
9.4.6.7.2 PCOS Diagnostic Market Size & Forecast, By Drug Class, 2021 – 2032
9.4.6.7.3 PCOS Diagnostic Market Size & Forecast, By Surgery Type, 2021 – 2032
9.4.6.7.4 PCOS Diagnostic Market Size & Forecast, By Distribution Channel, 2021 – 2032
9.5 Latin America
9.5.1 Key Trends
9.5.2 PCOS Diagnostic Market Size & Forecast, By Type of Diagnostic Test, 2021 – 2032
9.5.3 PCOS Diagnostic Market Size & Forecast, By Drug Class, 2021 – 2032
9.5.4 PCOS Diagnostic Market Size & Forecast, By Surgery Type, 2021 – 2032
9.5.5 PCOS Diagnostic Market Size & Forecast, By Distribution Channel, 2021 – 2032
9.5.6 PCOS Diagnostic Market Size & Forecast, By Country, 2021 – 2032
9.5.6.1 Brazil
9.5.6.1.1 PCOS Diagnostic Market Size & Forecast, By Type of Diagnostic Test, 2021 – 2032
9.5.6.1.2 PCOS Diagnostic Market Size & Forecast, By Drug Class, 2021 – 2032
9.5.6.1.3 PCOS Diagnostic Market Size & Forecast, By Surgery Type, 2021 – 2032
9.5.6.1.4 PCOS Diagnostic Market Size & Forecast, By Distribution Channel, 2021 – 2032
9.5.6.2 Argentina
9.5.6.2.1 PCOS Diagnostic Market Size & Forecast, By Type of Diagnostic Test, 2021 – 2032
9.5.6.2.2 PCOS Diagnostic Market Size & Forecast, By Drug Class, 2021 – 2032
9.5.6.2.3 PCOS Diagnostic Market Size & Forecast, By Surgery Type, 2021 – 2032
9.5.6.2.4 PCOS Diagnostic Market Size & Forecast, By Distribution Channel, 2021 – 2032
9.5.6.3 Mexico
9.5.6.3.1 PCOS Diagnostic Market Size & Forecast, By Type of Diagnostic Test, 2021 – 2032
9.5.6.3.2 PCOS Diagnostic Market Size & Forecast, By Drug Class, 2021 – 2032
9.5.6.3.3 PCOS Diagnostic Market Size & Forecast, By Surgery Type, 2021 – 2032
9.5.6.3.4 PCOS Diagnostic Market Size & Forecast, By Distribution Channel, 2021 – 2032
9.5.6.4 Colombia
9.5.6.4.1 PCOS Diagnostic Market Size & Forecast, By Type of Diagnostic Test, 2021 – 2032
9.5.6.4.2 PCOS Diagnostic Market Size & Forecast, By Drug Class, 2021 – 2032
9.5.6.4.3 PCOS Diagnostic Market Size & Forecast, By Surgery Type, 2021 – 2032
9.5.6.4.4 PCOS Diagnostic Market Size & Forecast, By Distribution Channel, 2021 – 2032
9.5.6.5 Rest of Latin America
9.5.6.5.1 PCOS Diagnostic Market Size & Forecast, By Type of Diagnostic Test, 2021 – 2032
9.5.6.5.2 PCOS Diagnostic Market Size & Forecast, By Drug Class, 2021 – 2032
9.5.6.5.3 PCOS Diagnostic Market Size & Forecast, By Surgery Type, 2021 – 2032
9.5.6.5.4 PCOS Diagnostic Market Size & Forecast, By Distribution Channel, 2021 – 2032
9.6 Middle East & Africa
9.6.1 Key Trends
9.6.2 PCOS Diagnostic Market Size & Forecast, By Type of Diagnostic Test, 2021 – 2032
9.6.3 PCOS Diagnostic Market Size & Forecast, By Drug Class, 2021 – 2032
9.6.4 PCOS Diagnostic Market Size & Forecast, By Surgery Type, 2021 – 2032
9.6.5 PCOS Diagnostic Market Size & Forecast, By Distribution Channel, 2021 – 2032
9.6.6 PCOS Diagnostic Market Size & Forecast, By Country, 2021 – 2032
9.6.6.1 UAE
9.6.6.1.1 PCOS Diagnostic Market Size & Forecast, By Type of Diagnostic Test, 2021 – 2032
9.6.6.1.2 PCOS Diagnostic Market Size & Forecast, By Drug Class, 2021 – 2032
9.6.6.1.3 PCOS Diagnostic Market Size & Forecast, By Surgery Type, 2021 – 2032
9.6.6.1.4 PCOS Diagnostic Market Size & Forecast, By Distribution Channel, 2021 – 2032
9.6.6.2 Saudi Arabia
9.6.6.2.1 PCOS Diagnostic Market Size & Forecast, By Type of Diagnostic Test, 2021 – 2032
9.6.6.2.2 PCOS Diagnostic Market Size & Forecast, By Drug Class, 2021 – 2032
9.6.6.2.3 PCOS Diagnostic Market Size & Forecast, By Surgery Type, 2021 – 2032
9.6.6.2.4 PCOS Diagnostic Market Size & Forecast, By Distribution Channel, 2021 – 2032
9.6.6.3 Qatar
9.6.6.3.1 PCOS Diagnostic Market Size & Forecast, By Type of Diagnostic Test, 2021 – 2032
9.6.6.3.2 PCOS Diagnostic Market Size & Forecast, By Drug Class, 2021 – 2032
9.6.6.3.3 PCOS Diagnostic Market Size & Forecast, By Surgery Type, 2021 – 2032
9.6.6.3.4 PCOS Diagnostic Market Size & Forecast, By Distribution Channel, 2021 – 2032
9.6.6.4 Egypt
9.6.6.4.1 PCOS Diagnostic Market Size & Forecast, By Type of Diagnostic Test, 2021 – 2032
9.6.6.4.2 PCOS Diagnostic Market Size & Forecast, By Drug Class, 2021 – 2032
9.6.6.4.3 PCOS Diagnostic Market Size & Forecast, By Surgery Type, 2021 – 2032
9.6.6.4.4 PCOS Diagnostic Market Size & Forecast, By Distribution Channel, 2021 – 2032
9.6.6.5 South Africa
9.6.6.5.1 PCOS Diagnostic Market Size & Forecast, By Type of Diagnostic Test, 2021 – 2032
9.6.6.5.2 PCOS Diagnostic Market Size & Forecast, By Drug Class, 2021 – 2032
9.6.6.5.3 PCOS Diagnostic Market Size & Forecast, By Surgery Type, 2021 – 2032
9.6.6.5.4 PCOS Diagnostic Market Size & Forecast, By Distribution Channel, 2021 – 2032
9.6.6.6 Rest of Middle East & Africa
9.6.6.6.1 PCOS Diagnostic Market Size & Forecast, By Type of Diagnostic Test, 2021 – 2032
9.6.6.6.2 PCOS Diagnostic Market Size & Forecast, By Drug Class, 2021 – 2032
9.6.6.6.3 PCOS Diagnostic Market Size & Forecast, By Surgery Type, 2021 – 2032
9.6.6.6.4 PCOS Diagnostic Market Size & Forecast, By Distribution Channel, 2021 – 2032
10. Competitive Landscape
10.1 Key Players' Positioning
10.2 Competitive Developments
10.2.1 Key Strategies Adopted (%), By Key Players, 2024
10.2.2 Year-Wise Strategies & Development, 2021 – 2025
10.2.3 Number of Strategies Adopted by Key Players, 2024
10.3 Market Share Analysis, 2024
10.4 Product/Service & Application Benchmarking
10.4.1 Product/Service Specifications & Features By Key Players
10.4.2 Product/Service Heatmap By Key Players
10.4.3 Application Heatmap By Key Players
10.5 Industry Start-Up & Innovation Landscape
10.6 Key Company Profiles
10.6 Key Company Profiles
10.6.1 F. Hoffmann-La Roche Ltd
10.6.1.1 Company Overview & Snapshot
10.6.1.2 Product/Service Portfolio
10.6.1.3 Key Company Financials
10.6.1.4 SWOT Analysis
10.6.2 Quest Diagnostics
10.6.2.1 Company Overview & Snapshot
10.6.2.2 Product/Service Portfolio
10.6.2.3 Key Company Financials
10.6.2.4 SWOT Analysis
10.6.3 Thermo Fisher Scientific Inc.
10.6.3.1 Company Overview & Snapshot
10.6.3.2 Product/Service Portfolio
10.6.3.3 Key Company Financials
10.6.3.4 SWOT Analysis
10.6.4 Siemens Healthineers
10.6.4.1 Company Overview & Snapshot
10.6.4.2 Product/Service Portfolio
10.6.4.3 Key Company Financials
10.6.4.4 SWOT Analysis
10.6.5 Bio-Rad Laboratories
10.6.5.1 Company Overview & Snapshot
10.6.5.2 Product/Service Portfolio
10.6.5.3 Key Company Financials
10.6.5.4 SWOT Analysis
10.6.6 Hologic Inc.
10.6.6.1 Company Overview & Snapshot
10.6.6.2 Product/Service Portfolio
10.6.6.3 Key Company Financials
10.6.6.4 SWOT Analysis
10.6.7 Vitrolife
10.6.7.1 Company Overview & Snapshot
10.6.7.2 Product/Service Portfolio
10.6.7.3 Key Company Financials
10.6.7.4 SWOT Analysis
10.6.8 Myriad Genetics Inc.
10.6.8.1 Company Overview & Snapshot
10.6.8.2 Product/Service Portfolio
10.6.8.3 Key Company Financials
10.6.8.4 SWOT Analysis
10.6.9 Ansh Labs
10.6.9.1 Company Overview & Snapshot
10.6.9.2 Product/Service Portfolio
10.6.9.3 Key Company Financials
10.6.9.4 SWOT Analysis
10.6.10 Diagnostica Stago Inc.
10.6.10.1 Company Overview & Snapshot
10.6.10.2 Product/Service Portfolio
10.6.10.3 Key Company Financials
10.6.10.4 SWOT Analysis
10.6.11 Beckman Coulter Inc.
10.6.11.1 Company Overview & Snapshot
10.6.11.2 Product/Service Portfolio
10.6.11.3 Key Company Financials
10.6.11.4 SWOT Analysis
10.6.12 Randox Laboratories Ltd.
10.6.12.1 Company Overview & Snapshot
10.6.12.2 Product/Service Portfolio
10.6.12.3 Key Company Financials
10.6.12.4 SWOT Analysis
10.6.13 GE Healthcare
10.6.13.1 Company Overview & Snapshot
10.6.13.2 Product/Service Portfolio
10.6.13.3 Key Company Financials
10.6.13.4 SWOT Analysis
10.6.14 Laboratory Corporation of America Holdings
10.6.14.1 Company Overview & Snapshot
10.6.14.2 Product/Service Portfolio
10.6.14.3 Key Company Financials
10.6.14.4 SWOT Analysis
10.6.15 SRL Diagnostics
10.6.15.1 Company Overview & Snapshot
10.6.15.2 Product/Service Portfolio
10.6.15.3 Key Company Financials
10.6.15.4 SWOT Analysis
10.6.16 Perrigo Company plc
10.6.16.1 Company Overview & Snapshot
10.6.16.2 Product/Service Portfolio
10.6.16.3 Key Company Financials
10.6.16.4 SWOT Analysis
10.6.17 Lupin
10.6.17.1 Company Overview & Snapshot
10.6.17.2 Product/Service Portfolio
10.6.17.3 Key Company Financials
10.6.17.4 SWOT Analysis
10.6.18 Astellas Pharma Inc.
10.6.18.1 Company Overview & Snapshot
10.6.18.2 Product/Service Portfolio
10.6.18.3 Key Company Financials
10.6.18.4 SWOT Analysis
10.6.19 Organon
10.6.19.1 Company Overview & Snapshot
10.6.19.2 Product/Service Portfolio
10.6.19.3 Key Company Financials
10.6.19.4 SWOT Analysis
10.6.20 ADVANZ PHARMA
10.6.20.1 Company Overview & Snapshot
10.6.20.2 Product/Service Portfolio
10.6.20.3 Key Company Financials
10.6.20.4 SWOT Analysis
11. Analyst Recommendations
11.1 SNS Insider Opportunity Map
11.2 Industry Low-Hanging Fruit Assessment
11.3 Market Entry & Growth Strategy
11.4 Analyst Viewpoint & Suggestions On Market Growth
12. Assumptions
13. Disclaimer
14. Appendix
14.1 List Of Tables
14.2 List Of Figures
An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.
Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.
The 5 steps process:
Step 1: Secondary Research:
Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.
Step 2: Primary Research
When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data. This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.
We at SNS Insider have divided Primary Research into 2 parts.
Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.
This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.
Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.
Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.
Step 3: Data Bank Validation
Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.
Step 4: QA/QC Process
After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.
Step 5: Final QC/QA Process:
This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.
Key Segments
By Type of Diagnostic Test
Hormone Tests
Luteinizing Hormone (LH)
Follicle-Stimulating Hormone (FSH)
Testosterone
Anti-Müllerian Hormone (AMH)
Estrogen
Blood Tests
Fasting Insulin
Glucose Tolerance Test
Lipid Profile
HbA1c
Imaging Tests
Transvaginal Ultrasound
Pelvic Ultrasound
Pelvic Examination
Genetic Testing
Other Tests (Thyroid Function Tests (TSH, T3, T4), Prolactin Test, DHEAS (Dehydroepiandrosterone Sulfate))
By Drug Class
Oral Contraceptives
Antiandrogens
Insulin-Sensitizing Agents
Antidepressants
Anti-Obesity Medications
By Surgery Type
Ovarian Wedge Resection
Laparoscopic Ovarian Drilling (LOD)
By Distribution Channel
Hospital Pharmacies
Drug Stores & Retail Pharmacies
Online Providers
Request for Segment Customization as per your Business Requirement: Segment Customization Request
Regional Coverage:
North America
US
Canada
Europe
Germany
France
UK
Italy
Spain
Russia
Poland
Rest of Europe
Asia Pacific
China
India
Japan
South Korea
Australia
ASEAN Countries
Rest of Asia Pacific
Middle East & Africa
UAE
Saudi Arabia
Qatar
Egypt
South Africa
Rest of Middle East & Africa
Latin America
Brazil
Argentina
Mexico
Colombia
Rest of Latin America
Request for Country Level Research Report: Country Level Customization Request
Available Customization
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
Detailed Volume Analysis
Criss-Cross segment analysis (e.g., Product X Application)
Competitive Product Benchmarking
Geographic Analysis
Additional countries in any of the regions
Customized Data Representation
Detailed analysis and profiling of additional market players